Items tagged with Treatment
Urgent action necessary to improve equitable access to bedaquiline-based regiments and achieve 1/4/6×24 (post with simple image)
Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.
India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline (post with simple image)
Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.
Updates from the 1/4/6x24 Campaign (post with simple image)
A few recent Campaign updates from Treatment Action Group and allies.
Contact firstname.lastname@example.org for more information on how to be part of the 1/4/6x24 Campaign.
TAG's 2022 Pipeline Report: TB Treatment (post with simple image)
Treatment Action Group launches the 2022 Tuberculosis Treatment Pipeline Report.
Action needed to scale up access to shorter, safer TB prevention and treatment regimens (post with simple image)
A push to include the latest WHO-recommended TB regimens in the current round of funding requests to the Global Fund.
1/4/6x24 Campaign videos & World TB Day Toolkit (post with simple image)
Treatment Action Group and the 1/4/6x24 Campaign Coalition launch the 1/4/6x24 World TB Day Toolkit to support advocacy the week of World TB Day for access to shorter, safer regimens for TB prevention and treatment.
The 1/4/6×24 Campaign Coalition welcomes India’s rejection of Johnson & Johnson’s patent evergreening tactic (post with simple image)
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key TB drug.
Page 97 of 97 · Total posts: 0←First 96 97